Special Issue

Ovarian Cancer Biomarkers, Diagnostic and Therapeutic Technologies

Message from the Guest Editors

Ovarian cancer remains one of the most lethal of gynaecological malignancies, characterised in most patients by recurrent, persistent disease and the rapid acquisition of chemo-resistance. Substantial molecular heterogeneity and co-existing phenotypes at diagnosis further complicate treatment choices and efficacy. Early diagnosis-ideally of pre-cancerous lesions, and particularly in asymptomatic women-remains a major challenge in ovarian cancer management. Equally as important, prognostic and predictive approaches are required to detect recurrence and enhance therapeutic management for patients in whom primary care is likely to fail. Combined with approaches to identify new druggable targets and therapeutic strategies—whether synergistic or stand-alone—research is poised to exert a substantial and positive impact over clinical ovarian cancer management. This Special Issue will focus on emerging technologies with the potential to improve the diagnosis, prognostic evaluation and therapeutic management ovarian cancers.

Guest Editors

Dr. Andrew Stephens

- 1. Department of Molecular and Translational Sciences, Monash University, Clayton 3168, Australia
- 2. Cleo Diagnostics Ltd., Melbourne 3000, Australia
- 3. Hudson Institute of Medical Research, Clayton 3168, Australia

Dr. Maree Bilandzic

Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia

Deadline for manuscript submissions

closed (31 March 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/77485

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

